(Q43791689)

English

Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer

scientific article published in September 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 November 2017

Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer (English)

1 reference

Europe PubMed Central

26 November 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

metastatic breast cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

J A Oshaughnessy

1

1 reference

Europe PubMed Central

26 November 2017

J Blum

2

1 reference

Europe PubMed Central

26 November 2017

V Moiseyenko

3

1 reference

Europe PubMed Central

26 November 2017

S E Jones

4

1 reference

Europe PubMed Central

26 November 2017

D Miles

5

1 reference

Europe PubMed Central

26 November 2017

D Bell

6

1 reference

Europe PubMed Central

26 November 2017

R Rosso

7

1 reference

Europe PubMed Central

26 November 2017

L Mauriac

8

1 reference

Europe PubMed Central

26 November 2017

B Osterwalder

9

1 reference

Europe PubMed Central

26 November 2017

H U Burger

10

1 reference

Europe PubMed Central

26 November 2017

S Laws

11

1 reference

Europe PubMed Central

26 November 2017

publication date

1 September 2001

1 reference

Europe PubMed Central

26 November 2017

Annals of Oncology

1 reference

Europe PubMed Central

26 November 2017

12

1 reference

Europe PubMed Central

26 November 2017

9

1 reference

Europe PubMed Central

26 November 2017

1247-1254

1 reference

Europe PubMed Central

26 November 2017

Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012281104865

7 January 2021

based on heuristic

inferred from DOI database lookup

Patient preferences for oral versus intravenous palliative chemotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012281104865

7 January 2021

based on heuristic

inferred from DOI database lookup

A study of quality of life in cancer patients receiving palliative chemotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012281104865

7 January 2021

based on heuristic

inferred from DOI database lookup

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012281104865

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012281104865

7 January 2021

based on heuristic

inferred from DOI database lookup

Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012281104865

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012281104865

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012281104865

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimizing chemotherapy for patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012281104865

7 January 2021

based on heuristic

inferred from DOI database lookup

Mitoxantrone, 5-fluorouracil and high-dose leucovorin (NFL) in the treatment of metastatic breast cancer: randomized comparison to cyclophosphamide, methotrexate and 5-fluorouracil (CMF) and attempts to improve efficacy by adding paclitaxel

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012281104865

7 January 2021

based on heuristic

inferred from DOI database lookup

"Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808)

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012281104865

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012281104865

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012281104865

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1012281104865

1 reference

Europe PubMed Central

26 November 2017

1 reference

Europe PubMed Central

26 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43791689&oldid=2103366392"